---
title: "CG Oncology, Inc. (CGON.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/CGON.US.md"
symbol: "CGON.US"
name: "CG Oncology, Inc."
industry: "生物技術"
---

# CG Oncology, Inc. (CGON.US)

| Item | Detail |
|------|--------|
| Industry | 生物技術 |
| Location | 美股市場 |
| Website | [cgoncology.com](https://cgoncology.com) |

## Company Profile

CG Oncology, Inc.是一家處于后期臨床階段的生物制藥公司，專注于為膀胱癌患者開發和商業化膀胱保護治療藥物。該公司正在開發 BOND-003，目前處于針對高風險卡介苗（BCG）無反應非肌肉侵襲性膀胱癌（NMIBC）患者的三期臨床試驗；CORE-001 正在進行二期臨床試驗，旨在治療高風險 BCG 無反應的 NMIBC 患者，採用克雷托斯替莫和帕博利珠單抗的聯合療法；CORE-002 則用于治療肌肉侵襲性膀胱癌患者，採用克雷托斯替莫和檢查點抑制劑 nivolumab 的聯合療法。該公司還在開發 PIVOT-006，這是一種克雷托斯替莫單藥治療，正在進行三期臨床試驗，適用于經膀胱腫瘤經...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-25T04:30:13.000Z

**Overall: C (0.48)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 72 / 401 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 217.84% |  |
| Net Profit YoY | -92.41% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 6.84 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 4.71B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 2.17M |  |


**Multi Score**: C

#### Profit Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -24.74% | E |
| Profit Margin | -6967.99% | E |
| Gross Margin | -1668.37% | E |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 217.84% | A |
| Net Profit YoY | -92.41% | E |
| Total Assets YoY | 32.12% | A |
| Net Assets YoY | 28.11% | A |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -1.44% | D |
| OCF YoY | 217.84% | A |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.00 | E |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 5.79% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - CG Oncology, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-24.74%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-6967.99%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-1668.37%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "217.84%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-92.41%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "32.12%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "28.11%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-1.44%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "217.84%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "5.79%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | ADMA生物制藥 (US.ADMA) | A | A | A | B | B | A |
| 02 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 03 | Rigel制藥 (US.RIGL) | A | A | A | C | B | A |
| 04 | OpGen (US.OPGN) | B | A | A | A | B | A |
| 05 | 福泰制藥 (US.VRTX) | A | B | C | B | C | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -31.07 | 526/604 | - | - | - |
| PB | 6.84 | 342/604 | 4.92 | 3.81 | 2.81 |
| PS (TTM) | 2164.70 | 316/604 | 3799.92 | 2953.92 | 1588.09 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-20T05:00:00.000Z

Total Analysts: **15**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 11 | 73% |
| Overweight | 4 | 27% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 58.91 |
| Highest Target | 108.00 |
| Lowest Target | 60.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/CGON.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/CGON.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/CGON.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.